CTSONasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Cytosorbents Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$4.96+0.85 (+20.68%)
Close on Oct 19, 2026
- Market cap
- $311.52M
- P/E (TTM)
- –
- Dividend yield
- –
Cytosorbents Corp revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total product sales | – | – | $31.08M | $29.36M | $40.11M | $39.45M | $22.77M | $20.25M | $13.38M | – | – | – |
| Other product sales | – | – | $69.69K | $787.20K | $111.87K | $110.40K | $220.10K | $109.03K | $126.90K | – | – | – |
| Government grants | – | – | $5.26M | $5.33M | $3.06M | $1.55M | $2.18M | $2.25M | $1.77M | – | – | – |
| CytoSorb sales | – | – | $31.02M | $28.57M | $40.00M | $39.34M | $22.55M | $20.14M | $13.25M | – | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | – | – | – | – | – | – | – | $95.50K | $126.90K | $0 | – | – |
| All other countries | – | – | – | – | – | – | – | $8.39M | $5.35M | $3.31M | – | – |
| Germany | – | – | – | – | – | – | – | $11.77M | $7.91M | $4.89M | – | – |
From the segment and revenue-disaggregation notes of Cytosorbents's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.